Putting the I in AML: Artificial Intelligence and Machine Learning in Acute Myeloid Leukemia
Preprint
- 5 August 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Acute myeloid leukemia (AML) produces more molecular, imaging, and clinical data per patient than any hematologist can hold in mind at once, and each revision of the WHO, ICC, and European LeukemiaNet (ELN) frameworks adds to the load. Artificial intelligence (AI) and machine learning (ML) now reach into every stage of AML care. Deep-learning models read therapy-relevant mutations directly from bone-marrow smears; automated flow-cytometry gating reproduces expert calls in under a minute; and the first AI pathology devices for hematology have cleared regulatory review and entered clinical use. Beyond diagnosis, ML captures the age-dependent weight of individual mutations that categorical ELN scoring misses, drug-response prediction for venetoclax–azacitidine has been validated across multiple external cohorts, and large language models are being tested for tumor-board support and trial matching. The next wave, from clonal-architecture modeling and single-cell foundation models to digital twins and reinforcement learning for adaptive dosing, could move AML management from reactive toward predictive, evolution-aware care. This review departs from existing AI-in-hematology surveys in three ways: we (i) restrict scope to AML and organize the field around clinical decision points rather than technology categories, (ii) grade every tool on a five-tier clinical-readiness level (CRL-AML 1–5), which exposes hundreds of models clustered at CRL-AML 1–2 and none yet in prospective clinical evaluation, and (iii) close with a numbered three-year agenda naming the consortia, datasets, and pragmatic trials needed to carry the field from publication to practice.Keywords
All Related Versions
- Version 1, 2026-08-05, Preprints
- Published version: Cells, 15 (17), 1539.
This publication has 138 references indexed in Scilit:
- Benefit-Risk Reporting for FDA-Cleared Artificial Intelligence−Enabled Medical DevicesJAMA Health Forum, 2025
- A Network‐Driven Framework for Drug Response Precision Prediction of Acute Myeloid LeukemiaAdvanced Science, 2025
- Generalizability of FDA-Approved AI-Enabled Medical Devices for Clinical UseJAMA Network Open, 2025
- Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and ManagementAmerican Journal of Hematology, 2025
- Classification of acute myeloid leukemia based on multi‐omics and prognosis prediction valueMolecular Oncology, 2025
- Models for the marrow: A comprehensive review of AI‐based cell classification methods and malignancy detection in bone marrow aspirate smearsHemaSphere, 2024
- Model‐Informed Reinforcement Learning for Enabling Precision Dosing Via Adaptive DosingClinical Pharmacology & Therapeutics, 2024
- A Perspective on Explainable Artificial Intelligence Methods: SHAP and LIMEAdvanced Intelligent Systems, 2024
- MAGIC‐DR: An interpretable machine‐learning guided approach for acute myeloid leukemia measurable residual disease analysisCytometry Part B: Clinical Cytometry, 2024
- Patient‐based prediction algorithm of relapse after allo‐HSCT for acute Leukemia and its usefulness in the decision‐making process using a machine learning approachCancer Medicine, 2019